New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 27, 2012
08:03 EDTOGXIOncoGenex reports positive data for compound OGX-427
OncoGenex announced that preclinical data utilizing their pipeline compound OGX-427 was presented at the 27th Annual EAU Congress.This preclinical study, along with previously reported preclinical data, further demonstrated the potential of OGX-427 to augment anti-cancer therapies and delay tumor progression. The study showed that when Hsp27 was decreased via OGX-427 treatment, the effect of the Hsp90 inhibitors was enhanced and tumor cell death was observed. The authors concluded OGX-427 in combination with Hsp90 inhibitors potentiated the effects of Hsp90, delayed tumor growth and prolonged survival in murine prostate cancer models.
News For OGXI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
August 27, 2015
09:57 EDTOGXIOncoGenex mentioned positively again by Agora Financial
August 13, 2015
16:22 EDTOGXIOncoGenex sees phase 3 Custirsen lung cancer trial results in 2H16
Subscribe for More Information
16:03 EDTOGXIOncoGenex reports Q2 EPS (26c), may not compare to consensus 34c
Reports Q2 revenue $4.03M, may not compare to consensus $21.40M. Reports cash and equivalents $60.2M. Says has sufficient funds for operations into late 4Q16.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use